Drugs / therapeutic autologous dendritic cells

Trials 28 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 112 trials
Phase 1 NCT01826877 Jan 2013 → Jul 2018 clear cell renal carcinoma Jonsson Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT00963521 Jun 2008 → May 2011 leukemia Institut Paoli-Calmettes Completed No outcome recorded
Phase 1 NCT00639639 Feb 2006 → Apr 2017 malignant glioma Gary Archer Ph.D. Completed No outcome recorded
Phase 1 NCT00128622 Sep 2005 → Mar 2007 breast cancer, colorectal cancer, lung cancer, malignant pancreatic neoplasm H. Kim Lyerly Completed No outcome recorded
Phase 1 NCT00098917 Feb 2005 → ? lung cancer Jonsson Comprehensive Cancer Center Terminated No outcome recorded
Phase 1 NCT00107185 Jan 2005 → Oct 2009 central nervous system neoplasm Jonsson Comprehensive Cancer Center Completed No outcome recorded
Phase 1 NCT00107211 Jan 2005 → Jul 2008 breast cancer Abramson Cancer Center at Penn Medicine Completed No outcome recorded
Phase 1 NCT00100971 Apr 2004 → Mar 2007 leukemia Boston Medical Center Terminated No outcome recorded
Phase 1 NCT00085488 Feb 2004 → Feb 2006 cutaneous melanoma Dartmouth-Hitchcock Medical Center Completed No outcome recorded
Phase 1 NCT00023985 Jan 2001 → Jul 2003 lung cancer Roswell Park Cancer Institute Completed No outcome recorded
Phase 1/24 trials
Phase 1/2 NCT03942328 Sep 2019 → May 2030 expected hepatocellular carcinoma, intrahepatic cholangiocarcinoma Mayo Clinic Recruiting No outcome recorded
Phase 1/2 NCT03325101 Nov 2017 → Jun 2020 cutaneous melanoma Mayo Clinic Terminated No outcome recorded
Phase 1/2 NCT00126685 Apr 2005 → ? cutaneous melanoma Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen Unknown No outcome recorded
Phase 1/2 NCT00012064 Jul 2000 → Apr 2011 cutaneous melanoma Lisata Therapeutics, Inc. Completed No outcome recorded
Phase 212 trials
Phase 2 NCT05518032 Oct 2024 → Oct 2026 colorectal carcinoma Roswell Park Cancer Institute Withdrawn No outcome recorded
Phase 2 NCT00814892 Jan → Dec 2009 prostate cancer Mayo Clinic Terminated No outcome recorded
Phase 2 NCT00436930 Dec 2006 → Oct 2012 cutaneous melanoma Hoag Memorial Hospital Presbyterian Completed No outcome recorded
Phase 2 NCT00499083 May 2006 → Jul 2009 breast cancer University of Nebraska Completed No outcome recorded
Phase 2 NCT00266110 Dec 2005 → Feb 2013 breast cancer UNC Lineberger Comprehensive Cancer Center Completed No outcome recorded
Phase 2 NCT00103142 Feb 2005 → Jun 2009 colorectal cancer, metastatic malignant neoplasm Michael Morse, MD Completed No outcome recorded
Phase 2 NCT00093522 Aug 2004 → ? kidney cancer St. Luke's Medical Center Unknown No outcome recorded
Phase 2 NCT00085397 Mar 2004 → ? cutaneous melanoma Dana-Farber Cancer Institute Unknown No outcome recorded
Phase 2 NCT00088985 Jan 2004 → Oct 2009 breast cancer UNC Lineberger Comprehensive Cancer Center Terminated No outcome recorded
Phase 2 NCT00027599 Dec 2001 → Jul 2007 prostate cancer National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 30 sources stand behind the page.

FieldValueCited text
Known as therapeutic autologous dendritic cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT00103142
27

NCT00639639

NCT03325101

NCT00107185

NCT00012064

NCT00085488

NCT00963521

NCT00005816

NCT00100971

NCT00128622

NCT01826877

NCT00085397

NCT00027599

NCT00093522

NCT00005992

NCT00107211

NCT00436930

NCT00001566

NCT00126685

NCT00001827

NCT00499083

NCT03942328

NCT00023985

NCT00088985

NCT00814892

NCT00266110

NCT05518032

NCT00098917

Known as CMV-DC vaccine “Patients receive CMV-DC vaccine as in arm I.” NCT00639639
Known as DCV “patient-specific autologous dendritic cell vaccines (DCV)” PMID 32316978 Apr 2020
Known as Renal tumor RNA-transfected dendritic cells Renal tumor RNA-transfected dendritic cells were administered to 10 evaluable study patients” PMID 12727829 May 2003
Action Deplete “Vaccines made from a person's tumor cells and white blood cells may make the body build an immune response to kill tumor cells.” NCT00023985
Modality Vaccine “initial priming peptide-pulsed antigen presenting cell (APC) vaccine is performed” NCT00001566
Route Other “injection” NCT00001566